<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976401</url>
  </required_header>
  <id_info>
    <org_study_id>AK-US-001-0101</org_study_id>
    <nct_id>NCT03976401</nct_id>
  </id_info>
  <brief_title>A Study of AKR-001 in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of AKR-001 in Subjects With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akero Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akero Therapeutics, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center evaluation of AKR-001 in a randomized, double-blind,
      placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F4
      NASH.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">March 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Main: Change from baseline in hepatic fat fraction assessed by MRI-PDFF</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Main: Percent change from baseline in hepatic fat fraction assessed by MRI-PDFF</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main: The responder: patients who achieved a clinically meaningful relative reduction of at least 30% in liver fat content as measured by MRI-PDFF</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main: Safety and tolerability of AKR-001 in subjects with NASH: Number of participants with treatment-related adverse events and serious adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>20 Weeks</time_frame>
    <description>Clinical and laboratory AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). System Organ Class (SOC), High-Level Group Term (HLGT), High Level Term (HLT), Preferred Term (PT), and Lower-Level Term (LLT) will be attached to the clinical database. AE severity will be graded using the CTCAE.
Summaries (number and percentage of subjects) of TEAEs and SAEs by SOC and PT will be provided by treatment group. Treatment-emergent AEs will also be summarized by relationship to study drugs and severity. In addition, TEAEs leading to premature discontinuation of study drugs and study, and SAEs leading to death will be summarized and listed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main: Responder based on NAFLD Activity Score (NAS) system: patients who had a decrease of ≥ 2 points in NAS with at least a 1-point reduction in either lobular inflammation or hepatocellular ballooning and with no concurrent worsening of fibrosis stage</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main: Change from baseline in ALT</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort C: Change from baseline in liver stiffness assessed by FibroScan®</measure>
    <time_frame>16 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>AKR-001 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AKR-001 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AKR-001 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Main Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AKR-001 Dose (Cohort C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Cohort C)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKR-001</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>AKR-001 Dose (Cohort C)</arm_group_label>
    <arm_group_label>AKR-001 Dose 1</arm_group_label>
    <arm_group_label>AKR-001 Dose 2</arm_group_label>
    <arm_group_label>AKR-001 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo (Cohort C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Males and non-pregnant, non-lactating females between 18 - 80 years of age inclusive,
             based on the date of the screening visit.

          -  Main Study only: Body mass index (BMI) &gt; 25 kg/m^2 (unless the patient has
             biopsy-proven NASH documented within the last 2 years).

          -  Main Study only: Must have confirmation of ≥ 10% liver fat content on MRI-PDFF at
             screening.

          -  Main Study only: Biopsy-proven NASH. Must have had a liver biopsy within 180 days of
             randomization with fibrosis stage 1 to 3 and a non-alcoholic fatty liver disease
             (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the
             following NAS components:

               -  Steatosis (scored 0 to 3),

               -  Ballooning degeneration (scored 0 to 2), and

               -  Lobular inflammation (scored 0 to 3)

          -  Cohort C only: FibroScan® measurement &gt; 13.1 kPa.

          -  Cohort C only: Cirrhosis due to NASH. Liver biopsy consistent with F4 fibrosis
             according to the NAS system, confirmed by the central reader.

        Exclusion Criteria:

          -  Weight gain or loss &gt; 5% in the 3 months prior to randomization or &gt; 10% in the 6
             months prior to screening.

          -  Type 1 and insulin-dependent Type 2 diabetes.

          -  Poorly controlled hypertension (blood pressure &gt; 160/100).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akero Study Director</last_name>
    <phone>650-487-6488</phone>
    <email>akr001@akerotx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 210</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 214</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 101</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 216</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 201</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 203</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 110</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 109</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 107</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 105</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 218</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 102</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 208</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 106</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 205</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 103</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 202</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akero Clinical Study Site</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akero Site 215</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

